An Experimental DUAL Model of Advanced Liver Damage
Open Access
- 11 March 2021
- journal article
- research article
- Published by Wolters Kluwer Health in Hepatology Communications
- Vol. 5 (6) , 1051-1068
Abstract
Individuals exhibiting an intermediate alcohol drinking pattern in conjunction with signs of metabolic risk present clinical features of both alcohol‐associated and metabolic‐associated fatty liver diseases. However, such combination remains an unexplored area of great interest, given the increasing number of patients affected. In the present study, we aimed to develop a preclinical DUAL (alcohol‐associated liver disease plus metabolic‐associated fatty liver disease) model in mice. C57BL/6 mice received 10% vol/vol alcohol in sweetened drinking water in combination with a Western diet for 10, 23, and 52 weeks (DUAL model). Animals fed with DUAL diet elicited a significant increase in body mass index accompanied by a pronounced hypertrophy of adipocytes, hypercholesterolemia, and hyperglycemia. Significant liver damage was characterized by elevated plasma alanine aminotransferase and lactate dehydrogenase levels, extensive hepatomegaly, hepatocyte enlargement, ballooning, steatosis, hepatic cell death, and compensatory proliferation. Notably, DUAL animals developed lobular inflammation and advanced hepatic fibrosis. Sequentially, bridging cirrhotic changes were frequently observed after 12 months. Bulk RNA‐sequencing analysis indicated that dysregulated molecular pathways in DUAL mice were similar to those of patients with steatohepatitis. Conclusion: Our DUAL model is characterized by obesity, glucose intolerance, liver damage, prominent steatohepatitis and fibrosis, as well as inflammation and fibrosis in white adipose tissue. Altogether, the DUAL model mimics all histological, metabolic, and transcriptomic gene signatures of human advanced steatohepatitis, and therefore serves as a preclinical tool for the development of therapeutic targets.Keywords
This publication has 47 references indexed in Scilit:
- Roles of PI3K/AKT/PTEN Pathway as a Target for Pharmaceutical TherapyThe Open Medicinal Chemistry Journal, 2013
- Histopathological algorithm and scoring system for evaluation of liver lesions in morbidly obese patientsHepatology, 2012
- NF-κB in the liver—linking injury, fibrosis and hepatocellular carcinomaNature Reviews Gastroenterology & Hepatology, 2011
- Standard operating procedures for describing and performing metabolic tests of glucose homeostasis in miceDisease Models & Mechanisms, 2010
- Fibrosis in Human Adipose Tissue: Composition, Distribution, and Link With Lipid Metabolism and Fat Mass LossDiabetes, 2010
- Laboratory Models Available to Study Alcohol‐Induced Organ Damage and Immune Variations: Choosing the Appropriate ModelAlcohol, Clinical and Experimental Research, 2010
- Positive relationship between dietary fat, ethanol intake, triglycerides, and hypothalamic peptides: counteraction by lipid-lowering drugsAlcohol, 2009
- Toll-like receptors as targets in chronic liver diseasesGut, 2009
- Mitochondrial dysfunction and oxidative stress in the pathogenesis of alcohol- and obesity-induced fatty liver diseasesFree Radical Biology and Medicine, 2008
- Apoptosis and Bcl-2 expression in the livers of patients with steatohepatitisEuropean Journal of Gastroenterology & Hepatology, 2006